June 23, 2021
Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs

March 11, 2021
Tvardi Therapeutics Appoints Michael Wyzga, Former CFO of Genzyme, to Board of Directors

June 23, 2021
Chasing ‘Holy Grail’ STAT3 Target, Houston Startup Refuels with $74M to Zero in on Liver Cancer

June 23, 2021
Tvardi Raises $74M to Advance STAT3 Inhibitors for Cancer, Fibrosis

July 06, 2020
Pharmacokinetics and pharmacodynamics of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease

April 26, 2020
Stat3 activation induces insulin resistance via a muscle-specific E3 ubiquitin ligase Fbxo40